Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: Requiring many specialities and services, NETs have complex pathways presenting a challenge to plan services in existing NHS structures
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author:
Authors: Khan M, Reynolds M, Lewis J, Bell C, Rees A,
Keywords: Service, commissioning, Mdt,
Introduction: Patients with NETs can experience gastrointestinal(GI) symptoms including diarrhoea, steatorrhoea and urgency.
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author:
Authors: Donnelly L, Tailor S, Reid K, Williams M, Lewis J,
Keywords: Quality of life, Diarrhea,
Introduction: Treatments in NETs have been studied for effects on tumour progression and carcinoid syndrome with minimal evidence on gastrointestinal(GI) symptom burden and impact on quality of life(QoL)
Conference: 13th Annual ENETSConcerence (2016)
Presenting Author:
Authors: Williams M, Reid K, Ng S, Benny A, Lewis J,
Keywords: Quality of life, symptoms,
#1466 Delays in Diagnosing Neuroendocrine Tumours by Secondary Care Specialities
Introduction: Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) are considered to be a diagnostic challenge, many patients presenting with metastatic disease to a number of specialities in secondary care
Conference: 13th Annual ENETSConcerence (2016)
Presenting Author:
Authors: Benny A, Ng S, Reid K, Williams M, Lewis J,
Keywords: Diagnosis, gastroenterology, symptoms,
Introduction: Data have shown that 38% of intended gluteal intramuscular (IM) injections with long-acting release octreotide were mistakenly given subcutaneously (SC); in carcinoid syndrome patients, this significantly increased the rate of flushing (P=0.005; Boyd 2013, Pancreas). Lanreotide depot(LD) recently became FDA-approved for the treatment of gastroenteropancreatic neuroendocrine tumors (120 mg Q4W) as a deep SC injection.
Conference: 13th Annual ENETSConcerence (2016)
Presenting Author: Manon A
Authors: Manon A, Wolin E, Chassaing C, Lewis A, Bertocchi L,
Keywords: lanreotide, Somatuline, pharmacokinetic, PK,